Kidney International Reports最新文献

英文中文

Ten Years of Kidney International Reports 十年肾脏国际报告

IF 5.7 2区医学 Q1 UROLOGY & NEPHROLOGY

Kidney International Reports

Pub Date : 2025-12-29 DOI: 10.1016/j.ekir.2025.103751

Jai Radhakrishan , Radha McLean , Sumit Mohan

引用次数: 0

Kidney Tubule Secretion and AKI After Cardiac Surgery 心脏手术后肾小管分泌与AKI的关系

IF 5.7 2区医学 Q1 UROLOGY & NEPHROLOGY

Kidney International Reports

Pub Date : 2025-12-24 DOI: 10.1016/j.ekir.2025.103746

Orlando M. Gutiérrez , Ashutosh Tamhane , Jennifer A. Frey , Ching Min Chu , Lauren Shingler , Alexander Keister , Alexander L. Bullen , Byron C. Jaeger , Suzanne E. Judd , Edward D. Siew , Michael G. Shlipak , Joseph V. Bonventre , Emily B. Levitan , Jesse C. Seegmiller , Henry E. Wang , Joachim H. Ix

Introduction

Endogenous measures of impaired kidney tubule secretion are associated with kidney function decline. Whether they associate with future acute kidney injury (AKI) risk is unclear.

Methods

In 397 participants of the Reasons for Geographic and Racial Differences in Stroke study who underwent coronary artery bypass graft (CABG) surgery (mean age: 66 years, 29% female), we examined the association of a summary secretion score of 11 endogenous secretion markers (measured at a median 5.5 years before CABG) with AKI risk following CABG, adjusting for confounders including estimated glomerular filtration rate (eGFR) and albuminuria.

Results

A total of 177 participants developed AKI (≥ 0.3 mg/dl or 1.5× creatinine increase) following CABG. Individuals who developed AKI were older, more likely to be men, have diabetes, lower eGFR and greater albuminuria at the baseline visit. In models adjusted for age, sex, race, urine creatinine, time from baseline to CABG, diabetes, hypertension, and body mass index, a higher (signifying better) secretion score was associated with lower risk of AKI (risk ratio [RR] comparing 4th to 1st quartile: 0.49, 95% confidence interval [CI]: 0.32–0.74). The results did not meaningfully differ after further adjusting for eGFR and albuminuria (RR: 0.58, 95% CI: 0.38–0.89), or when secretion score was analyzed as a continuous variable (RR per 1 SD higher score: 0.85, 95% CI: 0.71–1.01). Associations were stronger in women (RR: 0.75, 95% CI: 0.59–0.95) than men (RR: 0.89, 95% CI: 0.69–1.16) in fully adjusted models (P_interaction = 0.01).

Conclusion

In community-based adults, greater estimated tubular secretion at times of relative health is associated with lower risk of AKI following CABG.

肾小管分泌受损的内源性测量与肾功能下降有关。它们是否与未来急性肾损伤（AKI）风险相关尚不清楚。方法在397名接受冠状动脉旁路移植术（CABG）的卒中地理和种族差异研究参与者中（平均年龄：66岁，29%为女性），我们检查了11种内源性分泌标志物的总分泌评分（在CABG前5.5年测量）与CABG后AKI风险的关系，并调整了混杂因素，包括估计的肾小球滤过率（eGFR）和蛋白尿。结果177例患者冠脉搭桥后出现AKI（≥0.3 mg/dl或肌酐升高1.5倍）。在基线随访时，AKI患者年龄较大，更有可能是男性，患有糖尿病，eGFR较低，蛋白尿较多。在调整了年龄、性别、种族、尿肌酐、从基线到冠脉绕道时间、糖尿病、高血压和体重指数等因素的模型中，较高的分泌评分与较低的AKI风险相关（第4和第1四分位数的风险比[RR]: 0.49, 95%可信区间[CI]: 0.32-0.74）。在进一步调整eGFR和蛋白尿后（RR: 0.58, 95% CI: 0.38-0.89），或当分泌评分作为连续变量分析时（每1 SD高的评分RR: 0.85, 95% CI: 0.71-1.01），结果没有显著差异。在完全调整的模型中，女性的相关性（RR: 0.75, 95% CI: 0.59-0.95）强于男性（RR: 0.89, 95% CI: 0.69-1.16）（p - interaction = 0.01）。结论：以社区为基础的成年人，在相对健康的时期，更大的肾小管分泌与冠脉搭桥后AKI的风险较低相关。

{"title":"Kidney Tubule Secretion and AKI After Cardiac Surgery","authors":"Orlando M. Gutiérrez , Ashutosh Tamhane , Jennifer A. Frey , Ching Min Chu , Lauren Shingler , Alexander Keister , Alexander L. Bullen , Byron C. Jaeger , Suzanne E. Judd , Edward D. Siew , Michael G. Shlipak , Joseph V. Bonventre , Emily B. Levitan , Jesse C. Seegmiller , Henry E. Wang , Joachim H. Ix","doi":"10.1016/j.ekir.2025.103746","DOIUrl":"10.1016/j.ekir.2025.103746","url":null,"abstract":"<div><h3>Introduction</h3><div>Endogenous measures of impaired kidney tubule secretion are associated with kidney function decline. Whether they associate with future acute kidney injury (AKI) risk is unclear.</div></div><div><h3>Methods</h3><div>In 397 participants of the Reasons for Geographic and Racial Differences in Stroke study who underwent coronary artery bypass graft (CABG) surgery (mean age: 66 years, 29% female), we examined the association of a summary secretion score of 11 endogenous secretion markers (measured at a median 5.5 years before CABG) with AKI risk following CABG, adjusting for confounders including estimated glomerular filtration rate (eGFR) and albuminuria.</div></div><div><h3>Results</h3><div>A total of 177 participants developed AKI (≥ 0.3 mg/dl or 1.5× creatinine increase) following CABG. Individuals who developed AKI were older, more likely to be men, have diabetes, lower eGFR and greater albuminuria at the baseline visit. In models adjusted for age, sex, race, urine creatinine, time from baseline to CABG, diabetes, hypertension, and body mass index, a higher (signifying better) secretion score was associated with lower risk of AKI (risk ratio [RR] comparing 4th to 1st quartile: 0.49, 95% confidence interval [CI]: 0.32–0.74). The results did not meaningfully differ after further adjusting for eGFR and albuminuria (RR: 0.58, 95% CI: 0.38–0.89), or when secretion score was analyzed as a continuous variable (RR per 1 SD higher score: 0.85, 95% CI: 0.71–1.01). Associations were stronger in women (RR: 0.75, 95% CI: 0.59–0.95) than men (RR: 0.89, 95% CI: 0.69–1.16) in fully adjusted models (<em>P</em><sub>interaction</sub> = 0.01).</div></div><div><h3>Conclusion</h3><div>In community-based adults, greater estimated tubular secretion at times of relative health is associated with lower risk of AKI following CABG.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"11 3","pages":"Article 103746"},"PeriodicalIF":5.7,"publicationDate":"2025-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145929213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The PLA2R Paradox: Seropositive Membranous Nephropathy With Negative Staining PLA2R悖论：血清阳性膜性肾病伴阴性染色

IF 5.7 2区医学 Q1 UROLOGY & NEPHROLOGY

Kidney International Reports

Pub Date : 2025-12-24 DOI: 10.1016/j.ekir.2025.103750

Xuanli Tang , Biao Huang , Jie Zheng , Yuan Li , Dedong Kang , Wei Zhou , Feng Xu

引用次数: 0

Etiology of Chronic Renal Failure in Hodeida, Yemen 也门荷台达慢性肾衰竭的病因学

IF 5.7 2区医学 Q1 UROLOGY & NEPHROLOGY

Kidney International Reports

Pub Date : 2025-12-20 DOI: 10.1016/j.ekir.2025.103738

Nabeel Yahya Al-madwahi , Ahmed Hasan Batah , Muneer Gamil Alwesabi , Haitham Mohammed Jowah

引用次数: 0

Improving Lifelong Comprehensive Care Coordination in Nephropathic Cystinosis: Multidisciplinary Perspectives 改善肾病型胱氨酸病终身综合护理协调：多学科视角

IF 5.7 2区医学 Q1 UROLOGY & NEPHROLOGY

Kidney International Reports

Pub Date : 2025-12-18 DOI: 10.1016/j.ekir.2025.103735

Ladan Golestaneh , Elizabeth G. Ames , Maya H. Doyle , Cybele Ghossein , Paul C. Grimm , Jennifer L. Hewlett , Alaena Lim , Lauren S. Marzinelli , Kimberly J. Schmidt , Bonnie Smeryage , Joshua J. Zaritsky , Frederick J. Kaskel

Nephropathic cystinosis is a rare lysosomal storage disorder characterized by cellular cystine accumulation and progressive multiorgan damage. Before advances in diagnostics, transplantation, and disease-modifying therapy, cystinosis was considered a fatal pediatric disease, with most patients reaching kidney failure by approximately 10 years of age. Life expectancy has now expanded into the 50s and beyond, and the disease has been transformed into a chronic condition with a predominantly extrarenal phenotype in adulthood. Traditionally, nephrologists have played a central role as cystinosis “care quarterbacks” in pediatric settings, and patients often expect this to continue after transitioning to adult care. As such, nephrologists are increasingly tasked with monitoring for and addressing complications in organs other than the kidneys, in addition to coordinating referrals to clinicians within the nephrology clinic (e.g., nurses, advanced practice providers, pharmacists, dietitians, social workers, care coordinators, and transplant specialists) and across multiple specialties (e.g., neurologists, gastroenterologists, endocrinologists, ophthalmologists, and orthopedists). Although recently published expert guidance offers recommendations for the multidisciplinary management of cystinosis, gaps in the literature exist around strategies to reduce care fragmentation, overcome collaboration challenges, and enhance patient/family and clinician experiences. This review aimed to explore various approaches for care delivery optimization across the lifespan of patients with cystinosis as well as improve the current understanding of disease-, patient-, provider-, and system-related factors that influence treatment adherence, engagement, and long-term outcomes.

肾病型胱氨酸病是一种罕见的溶酶体贮积性疾病，以细胞胱氨酸积累和进行性多器官损害为特征。在诊断、移植和疾病改善治疗取得进展之前，胱氨酸病被认为是一种致命的儿科疾病，大多数患者在大约10岁时达到肾衰竭。预期寿命现在已经扩展到50岁以上，并且这种疾病已经转变为一种慢性疾病，在成年期主要表现为外源性表型。传统上，肾病学家在儿科设置中扮演了胱氨酸病“护理四分卫”的核心角色，患者通常期望在过渡到成人护理后继续这样做。因此，除了协调肾内科诊所的临床医生（如护士、高级执业医师、药剂师、营养师、社会工作者、护理协调员和移植专家）和跨多个专业（如神经科医生、胃肠科医生、内分泌科医生、眼科医生和骨科医生）的转诊外，肾内科医生越来越多地承担监测和处理肾脏以外器官并发症的任务。尽管最近出版的专家指南为胱氨酸病的多学科管理提供了建议，但在减少护理碎片化、克服协作挑战以及增强患者/家庭和临床医生经验的策略方面，文献存在空白。本综述旨在探索胱氨酸病患者整个生命周期中优化护理交付的各种方法，并提高当前对影响治疗依从性、参与和长期结果的疾病、患者、提供者和系统相关因素的理解。

{"title":"Improving Lifelong Comprehensive Care Coordination in Nephropathic Cystinosis: Multidisciplinary Perspectives","authors":"Ladan Golestaneh , Elizabeth G. Ames , Maya H. Doyle , Cybele Ghossein , Paul C. Grimm , Jennifer L. Hewlett , Alaena Lim , Lauren S. Marzinelli , Kimberly J. Schmidt , Bonnie Smeryage , Joshua J. Zaritsky , Frederick J. Kaskel","doi":"10.1016/j.ekir.2025.103735","DOIUrl":"10.1016/j.ekir.2025.103735","url":null,"abstract":"<div><div>Nephropathic cystinosis is a rare lysosomal storage disorder characterized by cellular cystine accumulation and progressive multiorgan damage. Before advances in diagnostics, transplantation, and disease-modifying therapy, cystinosis was considered a fatal pediatric disease, with most patients reaching kidney failure by approximately 10 years of age. Life expectancy has now expanded into the 50s and beyond, and the disease has been transformed into a chronic condition with a predominantly extrarenal phenotype in adulthood. Traditionally, nephrologists have played a central role as cystinosis “care quarterbacks” in pediatric settings, and patients often expect this to continue after transitioning to adult care. As such, nephrologists are increasingly tasked with monitoring for and addressing complications in organs other than the kidneys, in addition to coordinating referrals to clinicians within the nephrology clinic (e.g., nurses, advanced practice providers, pharmacists, dietitians, social workers, care coordinators, and transplant specialists) and across multiple specialties (e.g., neurologists, gastroenterologists, endocrinologists, ophthalmologists, and orthopedists). Although recently published expert guidance offers recommendations for the multidisciplinary management of cystinosis, gaps in the literature exist around strategies to reduce care fragmentation, overcome collaboration challenges, and enhance patient/family and clinician experiences. This review aimed to explore various approaches for care delivery optimization across the lifespan of patients with cystinosis as well as improve the current understanding of disease-, patient-, provider-, and system-related factors that influence treatment adherence, engagement, and long-term outcomes.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"11 3","pages":"Article 103735"},"PeriodicalIF":5.7,"publicationDate":"2025-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145980938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Corrigendum to “Supportive Evidence of Surrogate End Points Based on Treatment Effect of Corticosteroid in IgA Nephropathy” [Kidney International Reports Volume 11, Issue 2, 2026, Article 103588] “基于皮质类固醇治疗IgA肾病疗效的替代终点的支持性证据”的勘误表[肾脏国际报告第11卷，第2期，2026，第103588条]

IF 5.7 2区医学 Q1 UROLOGY & NEPHROLOGY

Kidney International Reports

Pub Date : 2025-12-18 DOI: 10.1016/j.ekir.2025.103716

Takaya Sasaki , Nobuo Tsuboi , Kentaro Koike , Hiroyuki Ueda , Masahiro Okabe , Shinya Yokote , Akihiro Shimizu , Keita Hirano , Tetsuya Kawamura , Takashi Yokoo , Yusuke Suzuki , J-IGACS Working Group

引用次数: 0

Licorice-Induced Pseudohyperaldosteronism Highlights an Underestimated Etiology of Hypertension 甘草诱导的假性醛固酮增多症强调了一个被低估的高血压病因

IF 5.7 2区医学 Q1 UROLOGY & NEPHROLOGY

Kidney International Reports

Pub Date : 2025-12-17 DOI: 10.1016/j.ekir.2025.103731

Jean-Joseph Bendjilali-Sabiani , Antoine Cardinale , Anaïs Lamy , Alix-Marie Pouget , Jean-Christophe Boyer , Véronique Taillard , Pascal Reboul

引用次数: 0

CKD in Migrants: From Epidemiology to Challenges 移民慢性肾病：从流行病学到挑战

IF 5.7 2区医学 Q1 UROLOGY & NEPHROLOGY

Kidney International Reports

Pub Date : 2025-12-16 DOI: 10.1016/j.ekir.2025.103726

Karen Courville , Vicente Sánchez-Polo , Roberta Arena , Greta Borelli , Lilio Hu , Miriam Di Nunzio , Gianluigi Zaza , Gaetano La Manna , Luca De Nicola , Michele Provenzano

Chronic kidney disease (CKD) is now considered a global health burden. In addition to the well-known clinical risk factors, social determinants of the disease such as poverty, low birthweight, and lack of access to health services play an important role, with the prevalence of disease modified by various socioeconomic factors, including migration. Herein, we explore the intersection of CKD and migration by examining how migrant populations can modify global prevalence and therapy of CKD global prevalence, including the challenges faced by migrant populations in accessing nephrology units. In addition, we provide suggestions for improving their care.

慢性肾脏疾病（CKD）现在被认为是一个全球性的健康负担。除了众所周知的临床风险因素外，该病的社会决定因素，如贫穷、低出生体重和缺乏获得保健服务的机会也起着重要作用，各种社会经济因素（包括移徙）改变了该病的流行程度。在此，我们通过研究移民人口如何改变CKD全球患病率和治疗方法，包括移民人口在进入肾脏病单位时面临的挑战，来探索CKD和移民的交集。此外，我们还提出了改善护理的建议。

引用次数: 0

A Pathway to High Quality Clinical Trials in IgA Vasculitis Nephritis: Meeting Proceedings From a Multiprofessional International Collaborative Workshop IgA血管炎肾炎的高质量临床试验途径：多专业国际合作研讨会会议记录

IF 5.7 2区医学 Q1 UROLOGY & NEPHROLOGY

Kidney International Reports

Pub Date : 2025-12-16 DOI: 10.1016/j.ekir.2025.103729

Louise Oni , Rona Smith , Seza Ozen , Chloe Williams , Elin Davies , Charlotte King , Paul Brogan , Mark Haas , Jonathan Barratt , Jeffrey Hafkin , Despina Eleftheriou , Karuna Keat , EMD Smith , Wen Ding , Chee Cheung , Caroline Platt , Evangéline Pillebout , Andrew Chetwynd , Areefa Alladin , Augusto Vaglio , Alan Salama

IgA vasculitis (IgAV) is an autoimmune disease that affects the small vessels of the skin, joints, gastrointestinal (GI) tract, and kidneys. In the long term, IgAV associated with nephritis (IgAV-N) can progress to kidney failure. Evidence-based clinical studies of IgAV-N are few, leading to huge variations in treatment approaches and suboptimal outcomes. The wealth of emerging efficacious treatments for IgA nephrology brings new opportunities to this disease. The aim of this report is to describe the proceedings of a multiprofessional collaborative workshop convened to identify the barriers to developing high quality evidence for patients with IgAV-N. A multiprofessional group consisting of 53 attendees from 13 countries met. The meeting was represented by a variety of professional backgrounds, including lay attendees, with different levels of expertise (32% professors and 19% midcareer doctors). Using predefined aims, key themes were extracted, and an action plan developed. Consensus was obtained that there is sufficient similarity between adults and children in terms of the organs involved, pathophysiology, histological features, and likely response to treatment. Important differences included the greater spontaneous improvement in children and worse kidney outcomes in some populations. It was agreed that patients at greatest risk of kidney failure should be the primary focus of initial clinical trials. Important considerations included the following: diagnostic classification for adult onset IgAV, observational data, evidence of scientific similarity to IgA nephropathy (IgAN), an age-inclusive approach to trial design, systemic disease secondary end points, and the inclusion of patient-reported outcomes. This manuscript communicates an expert-informed pathway to high-quality evidence for IgAV-N.

IgA血管炎（IgAV）是一种自身免疫性疾病，影响皮肤、关节、胃肠道和肾脏的小血管。长期来看，与肾炎相关的IgAV （IgAV- n）可发展为肾衰竭。基于证据的IgAV-N临床研究很少，导致治疗方法差异很大，结果不理想。新出现的有效治疗IgA肾病的方法为这种疾病带来了新的机会。本报告的目的是描述一个多专业合作研讨会的会议记录，该研讨会旨在确定为IgAV-N患者开发高质量证据的障碍。由来自13个国家的53名与会者组成的多专业小组举行了会议。与会人员来自各行各业，包括专业水平不同的非专业人士（32%为教授，19%为职业中期医生）。利用预先确定的目标，提取了关键主题，并制定了行动计划。人们一致认为，成人和儿童在受累器官、病理生理学、组织学特征和可能的治疗反应方面有足够的相似性。重要的差异包括儿童更大的自发改善和一些人群更差的肾脏预后。人们一致认为，肾功能衰竭风险最大的患者应该是初始临床试验的主要焦点。重要的考虑因素包括：成人发病IgAV的诊断分类、观察数据、与IgA肾病（IgAN）的科学相似性证据、试验设计的年龄包容性方法、全身性疾病次要终点，以及纳入患者报告的结局。这份手稿为IgAV-N提供了一条专家知情的高质量证据途径。

{"title":"A Pathway to High Quality Clinical Trials in IgA Vasculitis Nephritis: Meeting Proceedings From a Multiprofessional International Collaborative Workshop","authors":"Louise Oni , Rona Smith , Seza Ozen , Chloe Williams , Elin Davies , Charlotte King , Paul Brogan , Mark Haas , Jonathan Barratt , Jeffrey Hafkin , Despina Eleftheriou , Karuna Keat , EMD Smith , Wen Ding , Chee Cheung , Caroline Platt , Evangéline Pillebout , Andrew Chetwynd , Areefa Alladin , Augusto Vaglio , Alan Salama","doi":"10.1016/j.ekir.2025.103729","DOIUrl":"10.1016/j.ekir.2025.103729","url":null,"abstract":"<div><div>IgA vasculitis (IgAV) is an autoimmune disease that affects the small vessels of the skin, joints, gastrointestinal (GI) tract, and kidneys. In the long term, IgAV associated with nephritis (IgAV-N) can progress to kidney failure. Evidence-based clinical studies of IgAV-N are few, leading to huge variations in treatment approaches and suboptimal outcomes. The wealth of emerging efficacious treatments for IgA nephrology brings new opportunities to this disease. The aim of this report is to describe the proceedings of a multiprofessional collaborative workshop convened to identify the barriers to developing high quality evidence for patients with IgAV-N. A multiprofessional group consisting of 53 attendees from 13 countries met. The meeting was represented by a variety of professional backgrounds, including lay attendees, with different levels of expertise (32% professors and 19% midcareer doctors). Using predefined aims, key themes were extracted, and an action plan developed. Consensus was obtained that there is sufficient similarity between adults and children in terms of the organs involved, pathophysiology, histological features, and likely response to treatment. Important differences included the greater spontaneous improvement in children and worse kidney outcomes in some populations. It was agreed that patients at greatest risk of kidney failure should be the primary focus of initial clinical trials. Important considerations included the following: diagnostic classification for adult onset IgAV, observational data, evidence of scientific similarity to IgA nephropathy (IgAN), an age-inclusive approach to trial design, systemic disease secondary end points, and the inclusion of patient-reported outcomes. This manuscript communicates an expert-informed pathway to high-quality evidence for IgAV-N.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"11 3","pages":"Article 103729"},"PeriodicalIF":5.7,"publicationDate":"2025-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145915212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Atypical Anti–Glomerular Basement Membrane Disease 非典型抗肾小球基底膜病

IF 5.7 2区医学 Q1 UROLOGY & NEPHROLOGY

Kidney International Reports

Pub Date : 2025-12-16 DOI: 10.1016/j.ekir.2025.103732

Loreto Fernández-Lorente , Amir Shabaka , José María Mora-Gutiérrez , Fernando Caravaca-Fontán , María Maldonado-Martín , Virginia Cabello , Helena Marco , Alba Temprado , Carlos Rivera , Lucía Facal , Xoana Barros , Carmen Calderón González , Joaquín Manrique , Ángel Panizo Santos , Gema Fernández-Juárez

引用次数: 0

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Kidney International Reports

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀